Invention Grant
US09446019B2 Sparstolonin B based pharmaceutical agent for neuroblastoma treatment
有权
基于Sparstolonin B的药物治疗神经母细胞瘤
- Patent Title: Sparstolonin B based pharmaceutical agent for neuroblastoma treatment
- Patent Title (中): 基于Sparstolonin B的药物治疗神经母细胞瘤
-
Application No.: US14483445Application Date: 2014-09-11
-
Publication No.: US09446019B2Publication Date: 2016-09-20
- Inventor: Ambrish Kumar , Ugra Sen Singh , Daping Fan , Donald J. Dipette
- Applicant: University of South Carolina
- Applicant Address: US SC Columbia
- Assignee: University of South Carolina
- Current Assignee: University of South Carolina
- Current Assignee Address: US SC Columbia
- Agency: Dority & Manning, P.A.
- Main IPC: A01N43/16
- IPC: A01N43/16 ; A61K31/35 ; A61K31/353 ; A61K31/37

Abstract:
Use of sparstolonin B in inhibition of growth and/or viability of human neuroblastoma cells is described. The sparstolonin B can be naturally derived from the Chinese herb Sparganium stoloniferum or can be synthetic. The sparstolonin B is shown to be effective both in vitro and in vivo in inhibition of growth and/or viability of neuroblastoma cells of multiple different genetic backgrounds including N-myc amplified with wild p53 neuroblastoma cells, N-myc amplified with mutated p53 neuroblastoma cells, and N-myc nonamplified neuroblastoma cells.
Public/Granted literature
- US20150105454A1 Sparstolonin B Based Pharmaceutical Agent for Neuroblastoma Treatment Public/Granted day:2015-04-16
Information query
IPC分类: